endosergЭндокринная хирургияEndocrine Surgery2306-35132310-3965Типография «Печатных дел Мастер»10.14341/serg12732endoserg-12732Research ArticleКлинический случайClinical CaseОсобенности ведения пациентов с амиодарон-индуцированным тиреотоксикозом в реальной клинической практикеFeatures of managing patients with amiodarone-induced thyrotoxicosis in real clinical practicehttps://orcid.org/0000-0001-7911-2424МарковаТ. Н.MarkovaT. N.

Маркова Татьяна Николаевна, д.м.н., профессор

eLibrary SPIN: 5914-2890

Москва

Tatyana N. Markova, MD, Dr. Sci. (Med.), Professor

eLibrary SPIN: 5914-2890

Moscow

markovatn18@yandex.ruhttps://orcid.org/0000-0001-7098-4584БельцевичД. Г.BeltsevichD. G.

Бельцевич Дмитрий Германович, д.м.н., профессор РАН

eLibrary SPIN: 4475-6327

Москва

Dmitriy G. Beltsevich, MD, Dr. Sci. (Med.), Professor of RAS

eLibrary SPIN: 4475-6327

Moscow

belts67@gmail.comhttps://orcid.org/0000-0003-4701-4357КалиничеваЕ. А.KalinichevaE. A.

Калиничева Евгения Александровна, врач-эндокринолог

eLibrary SPIN: 5883-2551

123182, Москва, ул. Пехотная, д. 3

Evgeniia A. Kalinicheva, MD, endocrinologist

eLibrary SPIN: 5883-2551

3 Pekhotnaya str., Moscow, 123182

kea852@gmail.comhttps://orcid.org/0000-0001-7914-7264КошкоданА.KoshkodanA.

Кошкодан Александра, клинический ординатор

Москва

Alexandra Koshkodan, resident

Moscow

Akoshkodan@yandex.ruhttps://orcid.org/0000-0001-8093-1187СалаватоваН. М-Р.SalavatovaN. M-R.

Салаватова Нурьяна Магомед-Рашидовна, клинический ординатор

Москва

Nuryana M.-R.Salavatova, resident

Moscow

nice.mago@mail.ruhttps://orcid.org/0000-0002-8537-3804ГауноваК. А.GaunovaK. A.

Гаунова Камила Артуровна, клинический ординатор

Москва

Kamila A. Gaunova, resident

Moscow

gid.kam@yandex.ruМосковский государственный медико-стоматологический университет им. А.И. Евдокимова; ГКБ № 52РоссияMoscow State University of Medicine and DentistryRussian FederationНМИЦ эндокринологииРоссияNational Medical Research Center for EndocrinologyRussian FederationГКБ № 52РоссияMoscow City Clinical Hospital 52Russian FederationМосковский государственный медико-стоматологический университет им. А.И. ЕвдокимоваРоссияMoscow State University of Medicine and DentistryRussian Federation2022190120231612934Copyright © Маркова Т.Н., Бельцевич Д.Г., Калиничева Е.А., Кошкодан А., Салаватова Н.М., Гаунова К.А., 20232023Маркова Т.Н., Бельцевич Д.Г., Калиничева Е.А., Кошкодан А., Салаватова Н.М., Гаунова К.А.Markova T.N., Beltsevich D.G., Kalinicheva E.A., Koshkodan A., Salavatova N.M., Gaunova K.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.surg-endojournals.ru/jour/article/view/12732

Амиодарон является противоаритмическим препаратом, который широко используется в клинической практике для контроля различных типов аритмий. Одним из наиболее значимых побочных эффектов терапии амиодароном является дисфункция щитовидной железы, которая наблюдается примерно у 15–20% пациентов. В данной статье представлен клинический случай по ведению 55-летнего пациента с пароксизмальной формой фибрилляции предсердий, по поводу которой проводилась терапия амиодароном с развитием манифестного амиодарон-индуцированного тиреотоксикоза, рефрактерного к медикаментозной терапии глюкокортикостероидами и тиреостатиками. В связи с неэффективностью длительной медикаментозной терапии проведена тотальная тиреоидэктомия, которая привела к быстрому разрешению тиреотоксикоза и нормализации ритма сердца.

Amiodarone is an antiarrhythmic drug that is widely used in clinical practice to control various types of arrhythmias. One of the most significant side effects of amiodarone therapy is thyroid dysfunction, which is observed in about 15–20% of patients. This article presents a clinical case of a 55-year-old patient with a paroxysmal form of atrial fibrillation, for which amiodarone therapy was performed with the development of manifest amiodarone-induced thyrotoxicosis, refractory to drug therapy with glucocorticosteroids and thyrostatics. Due to the ineffectiveness of drug therapy, a total thyroidectomy was performed, which led to a rapid resolution of thyrotoxicosis and normalization of the heart rhythm.

щитовидная железаамиодаронамиодарон-индуцированный тиреотоксикозтиреоидэктомияamiodaroneamiodarone-induced thyrotoxicosisthyroidectomythyroidReferencesZimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circulation. 2012;125(2):381-389. doi: https://doi.org/10.1161/CIRCULATIONAHA.111.019927Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circulation. 2012;125(2):381-389. doi: https://doi.org/10.1161/CIRCULATIONAHA.111.019927Крюков Е.В., Потехин Н.П., Фурсов А.Н., и др. Алгоритм ведения пациентов, получающих амиодарон, в зависимости от функционального состояния щитовидной железы // Клиническая медицина. — 2017. — Т. 95. — №10. — С. 901-905. doi: https://doi.org/10.18821/0023-2149-2017-95-10-901-905Kryukov EV, Potekhin NP, Fursov AN, et al. Algorithm of management of patients treated with amiodarone depending on thyroid functional state. Clin Med. 2017;95(10):901-905. (In Russ.). doi: https://doi.org/10.18821/0023-2149-2017-95-10-901-905Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev. 2001;22(2):240-254. doi: https://doi.org/10.1210/edrv.22.2.0427Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev. 2001;22(2):240-254. doi: https://doi.org/10.1210/edrv.22.2.0427Censi S, Bodanza V, Manso J, et al. Amiodarone-induced thyrotoxicosis: Differential diagnosis using 99mTc-SestaMIBI and Target-to-Background Ratio (TBR). Clin Nucl Med. 2018;43(9):655-662. doi: https://doi.org/10.1097/RLU.0000000000002207Censi S, Bodanza V, Manso J, et al. Amiodarone-induced thyrotoxicosis: Differential diagnosis using 99mTc-SestaMIBI and Target-to-Background Ratio (TBR). Clin Nucl Med. 2018;43(9):655-662. doi: https://doi.org/10.1097/RLU.0000000000002207Свириденко Н.Ю., Платонова Н.М., Молашенко Н.В., и др. Эндокринные аспекты применения амиодарона в клинической практике (алгоритм наблюдения и лечения функциональных расстройств щитовидной железы) // Российский кардиологический журнал. — 2012. — №2. — С. 63-71.Sviridenko NJu, Platonova NM, Molashenko NV, et al. Endocrine aspects of amiodarone therapy in clinical practice (follow-up and treatment algorithm for patients with thyroid dysfunction). Russian Journal of Cardiology. 2012;(2):63-71. (In Russ.).Benjamens S, Dullaart RPF, Sluiter WJ, et al. The clinical value of regular thyroid function tests during amiodarone treatment. Eur J Endocrinol. 2017;177(1):9-14. doi: https://doi.org/10.1530/EJE-17-0018Benjamens S, Dullaart RPF, Sluiter WJ, et al. The clinical value of regular thyroid function tests during amiodarone treatment. Eur J Endocrinol. 2017;177(1):9-14. doi: https://doi.org/10.1530/EJE-17-0018Florek JB, Girzadas D. Amiodarone. [cited 2021, Jul 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482154/Florek JB, Girzadas D. Amiodarone. [cited 2021, Jul 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482154/Vassallo P, Trohman RG. Prescribing amiodarone: an evidencebased review of clinical indications. JAMA. 2007;298(11):1312-1322. doi: https://doi.org/10.1001/jama.298.11.1312Vassallo P, Trohman RG. Prescribing amiodarone: an evidencebased review of clinical indications. JAMA. 2007;298(11):1312-1322. doi: https://doi.org/10.1001/jama.298.11.1312Eskes SA, Wiersinga WM. Amiodarone and thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23(6):735-751. doi: https://doi.org/10.1016/j.beem.2009.07.001Eskes SA, Wiersinga WM. Amiodarone and thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23(6):735-751. doi: https://doi.org/10.1016/j.beem.2009.07.001Chiovato L, Martino E, Tonacchera M, et al. Studies on the in vitro cytotoxic effect of amiodarone. Endocrinology. 1994;134(5):2277-2282. doi: https://doi.org/10.1210/endo.134.5.8156930Chiovato L, Martino E, Tonacchera M, et al. Studies on the in vitro cytotoxic effect of amiodarone. Endocrinology. 1994;134(5):2277-2282. doi: https://doi.org/10.1210/endo.134.5.8156930Tomisti L, Rossi G, Bartalena L, et al. The onset time of amiodaroneinduced thyrotoxicosis (AIT) depends on AIT type. Eur J Endocrinol. 2014;171(3):363-368. doi: https://doi.org/10.1530/EJE-14-0267Tomisti L, Rossi G, Bartalena L, et al. The onset time of amiodaroneinduced thyrotoxicosis (AIT) depends on AIT type. Eur J Endocrinol. 2014;171(3):363-368. doi: https://doi.org/10.1530/EJE-14-0267Schaan BD, Cunha CP, Francisconi A, et al. Amiodaroneinduced thyroid dysfunction in a tertiary center in south Brazil. Arq Bras Endocrinol Metabol. 2005;49(6):916-922. doi: https://doi.org/10.1590/s0004-27302005000600010Schaan BD, Cunha CP, Francisconi A, et al. Amiodaroneinduced thyroid dysfunction in a tertiary center in south Brazil. Arq Bras Endocrinol Metabol. 2005;49(6):916-922. doi: https://doi.org/10.1590/s0004-27302005000600010Sidhu J, Jenkins D. Men are at increased risk of amiodaroneassociated thyrotoxicosis in the UK. QJM An Int J Med. 2003;96(12):949-950. doi: https://doi.org/10.1093/qjmed/hcg158Sidhu J, Jenkins D. Men are at increased risk of amiodaroneassociated thyrotoxicosis in the UK. QJM An Int J Med. 2003;96(12):949-950. doi: https://doi.org/10.1093/qjmed/hcg158Zosin I, Balaş M. Amiodarone-induced thyroid dysfunction in an iodine-replete area: epidemiological and clinical data. Endokrynol Pol. 2012;63(1):2-9.Zosin I, Balaş M. Amiodarone-induced thyroid dysfunction in an iodine-replete area: epidemiological and clinical data. Endokrynol Pol. 2012;63(1):2-9.Stan MN, Ammash NM, Warnes CA, et al. Body mass index and the development of amiodarone-induced thyrotoxicosis in adults with congenital heart disease – a cohort study. Int J Cardiol. 2013;167(3):821-826. doi: https://doi.org/10.1016/j.ijcard.2012.02.015Stan MN, Ammash NM, Warnes CA, et al. Body mass index and the development of amiodarone-induced thyrotoxicosis in adults with congenital heart disease – a cohort study. Int J Cardiol. 2013;167(3):821-826. doi: https://doi.org/10.1016/j.ijcard.2012.02.015Kinoshita S, Hayashi T, Wada K, et al. Risk factors for amiodaroneinduced thyroid dysfunction in Japan. J Arrhythm. 2016;32(6):474-480. doi: https://doi.org/10.1016/j.joa.2016.03.008Kinoshita S, Hayashi T, Wada K, et al. Risk factors for amiodaroneinduced thyroid dysfunction in Japan. J Arrhythm. 2016;32(6):474-480. doi: https://doi.org/10.1016/j.joa.2016.03.008Гринева Е.Н., Цой У.А., Каронова Т.Л., и др. Проект Федеральных клинических рекомендаций по диагностике и лечению амиодарон-индуцированной дисфункции щитовидной железы // Клиническая и экспериментальная тиреоидология. — 2020. — Т. 16. — №2. — С. 12-24. doi: https://doi.org/10.14341/ket12693Grineva EN, Tsoy UA, Karonova TL, et al. Draft of the federal clinical recommendations for diagnosisi and treatment of amiodarone-induced thyroid dysfunction. Clinical and experimental thyroidology. 2021;16(2):12-24. (In Russ.). doi: https://doi.org/10.14341/ket12693Campi I, Perego GB, Ravogli A, et al. Pulsed intravenous methylprednisolone combined with oral steroids as a treatment for poorly responsive type 2 amiodaroneinduced thyrotoxicosis. Eur J Endocrinol. 2019;181(5):519-524. doi: https://doi.org/10.1530/EJE-19-0515Campi I, Perego GB, Ravogli A, et al. Pulsed intravenous methylprednisolone combined with oral steroids as a treatment for poorly responsive type 2 amiodaroneinduced thyrotoxicosis. Eur J Endocrinol. 2019;181(5):519-524. doi: https://doi.org/10.1530/EJE-19-0515Kotwal A, Clark J, Lyden M, et al. Thyroidectomy for amiodarone-induced thyrotoxicosis: Mayo clinic experience. J Endocr Soc. 2018;2(11):1226-1235. (In Russ.)]. doi: https://doi.org/10.1210/js.2018-00259Kotwal A, Clark J, Lyden M, et al. Thyroidectomy for amiodarone-induced thyrotoxicosis: Mayo clinic experience. J Endocr Soc. 2018;2(11):1226-1235. (In Russ.)]. doi: https://doi.org/10.1210/js.2018-00259Tomisti L, Materazzi G, Bartalena L, et al. Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction. J Clin Endocrinol Metab. 2012;97(10):3515-3521. doi: https://doi.org/10.1210/jc.2012-1797Tomisti L, Materazzi G, Bartalena L, et al. Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction. J Clin Endocrinol Metab. 2012;97(10):3515-3521. doi: https://doi.org/10.1210/jc.2012-1797Cappellani D, Papini P, Pingitore A, et al. Comparison between total thyroidectomy and medical therapy for amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. 2020;105(1):242-251. doi: https://doi.org/10.1210/clinem/dgz041Cappellani D, Papini P, Pingitore A, et al. Comparison between total thyroidectomy and medical therapy for amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. 2020;105(1):242-251. doi: https://doi.org/10.1210/clinem/dgz041Tonnelier A, de Filette J, De Becker A, et al. Successful pretreatment using plasma exchange before thyroidectomy in a patient with amiodarone-induced thyrotoxicosis. Eur Thyroid J. 2017;6(2):108-112. doi: https://doi.org/10.1159/000453578Tonnelier A, de Filette J, De Becker A, et al. Successful pretreatment using plasma exchange before thyroidectomy in a patient with amiodarone-induced thyrotoxicosis. Eur Thyroid J. 2017;6(2):108-112. doi: https://doi.org/10.1159/000453578Saïe C, Ghander C, Saheb S, et al. Therapeutic plasma exchange in refractory hyperthyroidism. Eur Thyroid J. 2021;10(1):86-92. doi: https://doi.org/10.1159/000507019Saïe C, Ghander C, Saheb S, et al. Therapeutic plasma exchange in refractory hyperthyroidism. Eur Thyroid J. 2021;10(1):86-92. doi: https://doi.org/10.1159/000507019Tieken K, Paramasivan AM, Goldner W, et al. Therapeutic plasma exchange as a bridge to total thyroidectomy in patients with severe thyrotoxicosis. AACE Clin Case Reports. 2020;6(1):e14-e18. doi: https://doi.org/10.4158/ACCR-2019-0132Tieken K, Paramasivan AM, Goldner W, et al. Therapeutic plasma exchange as a bridge to total thyroidectomy in patients with severe thyrotoxicosis. AACE Clin Case Reports. 2020;6(1):e14-e18. doi: https://doi.org/10.4158/ACCR-2019-0132Simsir IY, Ozdemir M, Duman S, et al. Therapeutic plasmapheresis in thyrotoxic patients. Endocrine. 2018;62(1):144-148. doi: https://doi.org/10.1007/s12020-018-1661-xSimsir IY, Ozdemir M, Duman S, et al. Therapeutic plasmapheresis in thyrotoxic patients. Endocrine. 2018;62(1):144-148. doi: https://doi.org/10.1007/s12020-018-1661-x

The authors declare that there are no conflicts of interest present.